AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

At the ObesityWeek 2024, AstraZeneca Plc (NASDAQ:AZN) shared data abstracts highlighting early data from AZD5004/ECC5004. In ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

One of those trials of the drug, called AZD5004, will focus on reduction in body weight on average in obese and overweight ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

Eccogene will receive a $60 million payment from AstraZeneca (AZN), which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first ...

Eccogene will receive a $60 million payment from AstraZeneca (AZN), which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first ...

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, announced that it ...